
ProKidney Ord Shs Class A (NASDAQ:PROK) shares are trading sharply higher Wednesday morning, following a marked surge on Tuesday driven by positive clinical trial data for its chronic kidney disease (CKD) treatment.
The company’s shares are gaining again Wednesday as investors continue to cheer statistically significant and clinically meaningful results from its Phase 2 REGEN-007 trial for rilparencel.